Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Jung Min Lee(Kyung Hee University), Elise C. Kohn(National Cancer Institute), Jiuping Ji(Pancreatic Cancer Action Network), Bradford J. Wood(National Institutes of Health), Christina M. Annunziata(National Cancer Institute), Lori M. Minasian(National Cancer Institute), James H. Doroshow(National Cancer Institute), Tristan M. Sissung(National Institutes of Health), Nicolas Gordon(National Institutes of Health), Stanley Lipkowitz(Center for Cancer Research), Victoria L. Chiou(Center for Cancer Research), William D. Figg(National Cancer Institute), Elizabeth M. Swisher(University of Washington), John L. Hays(The Ohio State University), Minshu Yu(National Institutes of Health), Maria I. Harrell(Johns Hopkins University)
Cited by 43
Related Papers
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JAMA Oncology|2015|1k
Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing
|Nature Communications|2018|964